Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJul 27, 2026
DataAggregated Company Financials
Companies181
  • 7D-0.7%
  • 3M11.8%
  • 1Y10.2%
  • YTD15.0%

Last week, the Pharma industry hasn't moved much but Torrent Pharmaceuticals is up 4.1% in that time. As for the the longer term, the industry is up 10% over the past 12 months. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 27 Jul 2026₹23.7t₹4.4t₹631.6b29.3x37.5x5.4x
Wed, 24 Jun 2026₹23.0t₹4.5t₹642.9b29.8x35.8x5.1x
Fri, 22 May 2026₹22.4t₹4.5t₹635.9b29.3x35.3x5x
Sun, 19 Apr 2026₹20.5t₹4.3t₹621.0b28x33x4.7x
Tue, 17 Mar 2026₹20.3t₹4.3t₹621.2b25.5x32.7x4.7x
Thu, 12 Feb 2026₹20.2t₹4.3t₹616.4b28.3x32.7x4.7x
Sat, 10 Jan 2026₹20.3t₹4.2t₹613.3b28.5x33.1x4.8x
Mon, 08 Dec 2025₹20.6t₹4.2t₹612.9b29x33.6x4.9x
Wed, 05 Nov 2025₹20.3t₹4.1t₹596.1b30.2x34.1x5x
Fri, 03 Oct 2025₹20.0t₹4.1t₹588.1b30.6x34.1x4.9x
Sun, 31 Aug 2025₹20.0t₹4.1t₹589.1b29.6x33.9x4.9x
Tue, 29 Jul 2025₹20.9t₹4.0t₹597.0b32.5x35x5.2x
Thu, 26 Jun 2025₹20.1t₹4.0t₹595.3b32.7x33.8x5.1x
Sat, 24 May 2025₹19.8t₹4.0t₹580.2b31.8x34x4.9x
Mon, 21 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Wed, 19 Mar 2025₹19.1t₹3.9t₹559.4b28.7x34.1x4.9x
Fri, 14 Feb 2025₹19.3t₹3.9t₹550.6b28.8x35.1x5x
Sun, 12 Jan 2025₹20.5t₹3.8t₹527.0b33.7x38.9x5.4x
Tue, 10 Dec 2024₹20.7t₹3.8t₹526.7b36.2x39.4x5.4x
Thu, 07 Nov 2024₹21.3t₹3.8t₹508.0b39.9x41.9x5.6x
Sat, 05 Oct 2024₹21.4t₹3.7t₹492.6b41.2x43.5x5.7x
Mon, 02 Sep 2024₹21.2t₹3.7t₹492.4b39.8x43x5.7x
Wed, 31 Jul 2024₹19.5t₹3.7t₹461.3b38.2x42.3x5.3x
Fri, 28 Jun 2024₹17.4t₹3.6t₹448.3b33.6x38.8x4.9x
Sun, 26 May 2024₹17.1t₹3.5t₹443.8b33.4x38.5x4.8x
Tue, 23 Apr 2024₹16.6t₹3.5t₹418.9b33.2x39.6x4.8x
Thu, 21 Mar 2024₹16.4t₹3.5t₹418.7b31.8x39.2x4.7x
Sat, 17 Feb 2024₹16.9t₹3.5t₹418.9b33.7x40.4x4.9x
Mon, 15 Jan 2024₹15.7t₹3.4t₹395.3b35.2x39.6x4.6x
Wed, 13 Dec 2023₹14.1t₹3.4t₹395.1b31.3x35.7x4.2x
Fri, 10 Nov 2023₹13.6t₹3.3t₹388.9b30.1x35.1x4.1x
Sun, 08 Oct 2023₹13.1t₹3.3t₹369.9b30.1x35.4x4x
Tue, 05 Sep 2023₹12.9t₹3.3t₹367.0b29.8x35x3.9x
Thu, 03 Aug 2023₹12.7t₹3.2t₹345.8b29.4x36.7x4x
Price to Earnings Ratio

36.7x


Total Market Cap: ₹12.7tTotal Earnings: ₹345.8bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 22% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-1.36%
Healthcare-0.67%
Pharma-0.72%
Pharma-0.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LAURUSLABS Laurus Labs₹1.71k9.9%
+₹83.4b		92.7%PE84.6x
SUNPHARMA Sun Pharmaceutical Industries₹1.97k0.9%
+₹41.5b		15.9%PE41.3x
PPLPHARMA Piramal Pharma₹192.057.4%
+₹17.5b		-6.0%PS2.9x
EMCURE Emcure Pharmaceuticals₹1.92k3.4%
+₹12.1b		37.2%PE39.5x
500660 GlaxoSmithKline Pharmaceuticals₹2.55k2.6%
+₹10.9b		-17.4%PE41.7x

Latest News

LAURUSLABS
₹1,601.20
Laurus Labs
7D
2.7%
1Y
80.1%
Analysis Article • 2h

Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. The company...
ACUTAAS
₹3,259.50
Acutaas Chemicals
7D
-10.9%
1Y
183.9%
CIPLA
₹1,410.60
Cipla
7D
-2.2%
1Y
-10.3%
Analysis Article • Jul 26

Cipla Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, Cipla Limited ( NSE:CIPLA ) recently reported its first-quarter numbers. Revenues were in line with...
ALKEM
₹5,633.50
Alkem Laboratories
7D
1.3%
1Y
12.4%
ZYDUSLIFE
₹1,108.70
Zydus Lifesciences
7D
-3.1%
1Y
13.5%
500124
₹1,152.60
Dr. Reddy's Laboratories
7D
-5.8%
1Y
-10.4%
Narrative Update • Jul 23

500124: New Biologics And Diabetes Launches Will Drive Future Upside

Analysts have trimmed their price target on Dr. Reddy's Laboratories from ₹1,679 to about ₹1,600, citing updated assumptions that combine slightly higher projected revenue growth and profit margins with a lower future P/E multiple. What's in the News Dr. Reddy's Laboratories reported that the USFDA completed a Pre License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad, issuing a Form 483 with seven observations that the company plans to address within the required timeline.
500257
₹2,369.45
Lupin
7D
-3.0%
1Y
21.5%
SANOFICONR
₹4,674.70
Sanofi Consumer Healthcare India
7D
3.2%
1Y
-5.8%
EMCURE
₹1,881.00
Emcure Pharmaceuticals
7D
1.1%
1Y
34.1%
RUBICON
₹1,520.20
Rubicon Research
7D
5.6%
1Y
n/a
500660
₹2,513.25
GlaxoSmithKline Pharmaceuticals
7D
1.1%
1Y
-18.6%
IPCALAB
₹1,762.70
Ipca Laboratories
7D
-4.1%
1Y
18.9%
Narrative Update • Jul 17

IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential

The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
MANKIND
₹2,507.20
Mankind Pharma
7D
-2.3%
1Y
-1.4%
500420
₹4,959.80
Torrent Pharmaceuticals
7D
4.1%
1Y
37.7%
SUNPHARMA
₹1,941.10
Sun Pharmaceutical Industries
7D
-0.8%
1Y
14.0%
CORONA
₹2,113.00
CORONA Remedies
7D
3.3%
1Y
n/a
Narrative Update • Jun 26

CORONA: Board Decisions On Results And Dividend Will Shape Balanced Outlook

Analysts have raised their fair value estimate for CORONA Remedies from ₹1,705 to ₹1,929. This change reflects updated assumptions for revenue growth, profit margins and future P/E expectations.